Curasight

In connection with the annual report, we have updated our Investment Case One-pager for Curasight. 2025 marked a defining transition for the company — from building and validating its uPAR platform to actively advancing its therapeutic program uTREAT into the clinic. The highlight of the year was the dosing of the first patient in the Phase 1 glioblastoma trial in December, marking the initiation of Curasight's first-ever clinical trial under its therapeutic platform. Combined with a strengthened capital base and continued progress on the diagnostic platform uTRACE, the company enters 2026 as an active clinical-stage radioligand therapy developer with two significant data readouts on the horizon.

Hvis du ikke deltog i eventet i går, eller gerne vil se præsentationen igen med Curasights CEO Ulrich Krasilnikoff og CSO Andreas Kjær, kan du se hele præsentationen her:

Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen.

Dagens aktienyheder 26/02-2026: North Media, Impero, Gubra, Agillic, Hafnia, TORM, Curasight og Føroya Banki

I dagens Morgenbørs ser vi ind i en lidt blandt åbning, hvor amerikanske og asiatiske futures er i minus imens Europa handler i plus. Herhjemme fokus på Ørsted.

Dagens aktienyheder med Trifork, Curasight og DS NORDEN

Curasight has entered a new clinical phase with both arms of its uPAR-based theranostic platform now in clinical development, following the successful first patient dosing in the Phase I uTREAT® trial in glioblastoma and continued progress in the Phase II uTRACE® prostate cancer study under the partnership with Curium. With diagnostic proof-of-concept already established across multiple indications, the transition of uTREAT® into human trials materially expands the company’s addressable market and shifts investor focus toward the therapeutic upside embedded in the platform.

Dagens aktienyheder 19/12-2025: Roblon, GreenMobility og Curasight